Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAX-GI
- Development stage
- Preclinical
- Lead developer
- Vaxcyte
- Modality
- Vaccines & Immunotherapeutics
01
Overview
VAX-GI is a preclinical-stage vaccine candidate being developed by Vaxcyte to prevent shigellosis (bacillary dysentery) caused by *Shigella* bacteria. The vaccine is produced using Vaxcyte's proprietary XpressCF™ cell-free protein synthesis platform, which allows for the production of complex proteins and antigens that are otherwise difficult to manufacture. The program is a collaboration with the University of Maryland, Baltimore, and has received significant funding through research grants from the National Institutes of Health (NIH). VAX-GI aims to provide broad protection against the various species and serotypes of *Shigella* that cause severe diarrheal disease globally.
- Other names
- Shigella vaccine candidate
Beyond the preview
Go deeper on VAX-GI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAX-GI.